Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PRAME Expression in HPV-associated and Differentiated Vulvar Intraepithelial Neoplasia-associated Vulvar Squamous Neoplasia.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026

Same author

HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026

Same author

MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Metastatic Triple-negative Breast Cancer Patients.

Applied immunohistochemistry & molecular morphology : AIMM·2026

Same author

Incidental Intraplacental Choriocarcinoma in the Setting of Intrauterine Fetal Demise.

Case reports in obstetrics and gynecology·2026

Same author

Endometrial Carcinoma of Gastrointestinal-type (EMCG): Incidence, Molecular Features, and Distinction From Other Endometrial Cancers With Gastrointestinal Marker Immunoexpression.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2026

Same author

Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.

International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists·2025

Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Xiangqian Guo¹, Vickie Y Jo², Anne M Mills³

¹Department of Pathology, Stanford University School of Medicine, Stanford, California.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|April 22, 2015

Summary

This summary is machine-generated.

Three molecular subtypes of leiomyosarcoma were confirmed in independent cohorts. These subtypes correlate with distinct clinical outcomes, paving the way for subtype-specific targeted therapies for leiomyosarcoma.

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Area of Science:

Oncology
Molecular Biology
Genomics

Background:

Leiomyosarcoma is a rare smooth muscle cancer with unknown molecular heterogeneity.
Currently, no targeted therapies exist for leiomyosarcoma, necessitating molecular subtyping for treatment evaluation.

Purpose of the Study:

To confirm previously identified molecular subtypes of leiomyosarcoma in independent patient cohorts.
To identify diagnostic markers and assess the clinical relevance of leiomyosarcoma subtypes.

Main Methods:

Expression profiling of 99 leiomyosarcoma cases using 3'end RNA-Sequencing (3SEQ).
Consensus clustering to determine molecular subtypes.
Validation using The Cancer Genome Atlas (TCGA) data and immunohistochemistry.

Main Results:

Three distinct molecular subtypes of leiomyosarcoma were confirmed across independent datasets.
Identified LMOD1 and ARL4C as diagnostic markers for subtype I and II leiomyosarcoma, respectively.
Subtype I associated with good prognosis in extrauterine cases; Subtype II associated with poor prognosis in both uterine and extrauterine leiomyosarcoma.

Conclusions:

The existence of three molecular subtypes in leiomyosarcoma is confirmed, each linked to specific clinical outcomes.
These findings support a subtype-specific targeted treatment approach for leiomyosarcoma.